TrialRMD open2024

Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL.

Laura C Coates et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.